BELLINGER ANDREW (Chief Scientific Officer) sold 75.0% of their position (15K shares) of VERVE THERAPEUTICS, INC. on the open market
Open‑market sale worth $580.5K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 12/27/2021ACC: 0000899243-21-049814
Officer· Chief Scientific Officer
Since Jun 2021
-15K
Net shares
Net seller
$580.5K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
15K acquired · 30K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+15K
Price / share
$1.48
Trade value
$22.20K
% of position
300.0%
12/22/2021
5K→20K
Common Stock
Direct
Shares
−1.97K
Price / share
$37.42
Trade value
$73.64K
% of position
9.8%
12/22/2021
20K→18.03K
Common Stock
Direct
Shares
−8.16K
Price / share
$38.60
Trade value
$315.03K
% of position
45.3%
12/22/2021
18.03K→9.87K
Common Stock
Direct
Shares
−4.87K
Price / share
$39.37
Trade value
$191.80K
% of position
49.3%
12/22/2021
9.87K→5K
Total
Net shares
+0.00
Net value
-$558.27K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/22/2021 | M · Option Exercise | +15K | $1.48 | $22.20K | 300.0% | 5K | 20K |
| Common Stock Direct | 12/22/2021 | S · Sale | −1.97K | $37.42 | $73.64K | 9.8% | 20K | 18.03K |
| Common Stock Direct | 12/22/2021 | S · Sale | −8.16K | $38.60 | $315.03K | 45.3% | 18.03K | 9.87K |
| Common Stock Direct | 12/22/2021 | S · Sale | −4.87K | $39.37 | $191.80K | 49.3% | 9.87K | 5K |
| Total | +0.00 | -$558.27K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
15K shares
Shares
−15K
Strike price
1.48
Held after
147K
Exercisable
—
12/22/2021
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock15K shares | 12/22/2021 | M · Option Exercise | −15K | 1.48 | — | 147K |